Pulling the Plug on Cancer Cell Communication. Stephen M. Ansell, MD, PhD Mayo Clinic

Similar documents
Waldenström Macroglobulinemia: The Burning Questions. IWMF Ed Forum May Morie Gertz MD, MACP

Malignant Lymphomas and Plasma Cell Myeloma

specific B cells Humoral immunity lymphocytes antibodies B cells bone marrow Cell-mediated immunity: T cells antibodies proteins

FastTest. You ve read the book now test yourself

chronic leukemia lymphoma myeloma differentiated 14 September 1999 Pre- Transformed Ig Surface Surface Secreted Myeloma Major malignant counterpart

Multiple Myeloma and Colorectal Cancer

B Cells and Antibodies

A Rare Image. Dean M. Cestari, MD Fred Jakobiec, MD Fred Hochberg, MD Joseph F. Rizzo III, MD Rebecca C. Stacy, MD PhD

Lymphoplasmacytic Lymphoma. Hematology fellows conference 4/12/2013 Christina Fitzmaurice, MD, MPH

MULTIPLE MYELOMA. Dr Malkit S Riyat. MBChB, FRCPath(UK) Consultant Haematologist

Monoclonal Gammopathy of Undetermined Significance (MGUS) Facts

How do plasma cells survive

Activation and effector functions of HMI

Microbiology AN INTRODUCTION EIGHTH EDITION

UNDERSTANDING MULTIPLE MYELOMA AND LABORATORY VALUES Benjamin Parsons, DO Gundersen Health System Center for Cancer and

SOUTHWEST ONCOLOGY GROUP CLINICAL RESEARCH ASSOCIATE (CRA) MANUAL. MYELOMA CHAPTER 10 REVISED: March 2008

HUMORAL IMMUNE RE- SPONSES: ACTIVATION OF B CELLS AND ANTIBODIES JASON CYSTER SECTION 13

LEUKEMIA LYMPHOMA MYELOMA Advances in Clinical Trials

The Immune System: A Tutorial

LYMPHOMA. BACHIR ALOBEID, M.D. HEMATOPATHOLOGY DIVISION PATHOLOGY DEPARTMENT Columbia University/ College of Physicians & Surgeons

The immune system. Bone marrow. Thymus. Spleen. Bone marrow. NK cell. B-cell. T-cell. Basophil Neutrophil. Eosinophil. Myeloid progenitor

Chapter 43: The Immune System

Immuno-Oncology Therapies to Treat Lung Cancer

What is Cancer? Cancer is a genetic disease: Cancer typically involves a change in gene expression/function:

B cell activation and Humoral Immunity

Multiple Myeloma Patient s Booklet

2) Macrophages function to engulf and present antigen to other immune cells.

Report series: General cancer information

Plasma cell dyscrasias Mark Drayson

Bone Marrow Evaluation for Lymphoma. Faizi Ali, MD Hematopathology Fellow William Beaumont Hospital

Interesting Case Review. Renuka Agrawal, MD Dept. of Pathology City of Hope National Medical Center Duarte, CA

B-cell Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

B Cell Generation, Activation & Differentiation. B cell maturation

Name (print) Name (signature) Period. (Total 30 points)

Things You Don t Want to Miss in Multiple Myeloma

Genomic Analysis of Mature B-cell Malignancies

Overview. Transcriptional cascades. Amazing aspects of lineage plasticity. Conventional (B2) B cell development

CLL: Disease Course, Treatment, Diagnosis, and Biomarkers

The Body s Defenses CHAPTER 24

An overview of CLL care and treatment. Dr Dean Smith Haematology Consultant City Hospital Nottingham

INSERM/ A. Bernheim. Overcoming clinical relapse in multiple myeloma by understanding and targeting the molecular causes of drug resistance

T Cell Maturation,Activation and Differentiation

TABLE OF CONTENTS. Multiple Myeloma / Plasma Cell Leukemia Pre-HSCT Data

Targeted Therapy What the Surgeon Needs to Know

Updating the 2008 WHO Classification of Small B cell lymphomas Elias Campo

Cancer Immunotherapy: Can Your Immune System Cure Cancer? Steve Emerson, MD, PhD Herbert Irving Comprehensive Cancer Center

LESSON 3.5 WORKBOOK. How do cancer cells evolve? Workbook Lesson 3.5

LESSON 3: ANTIBODIES/BCR/B-CELL RESPONSES

Understanding the immune response to bacterial infections

CLINICAL POLICY Department: Medical Management Document Name: Opdivo Reference Number: CP.PHAR.121 Effective Date: 07/15

Mature Lymphoproliferative disorders (2): Mature B-cell Neoplasms. Dr. Douaa Mohammed Sayed

Drug Development Services

Treatment of low-grade non-hodgkin lymphoma

Update in Hematology Oncology Targeted Therapies. Mark Holguin

Your Immune System & Lung Cancer Treatment

Special report. Chronic Lymphocytic Leukemia (CLL) Genomic Biology 3020 April 20, 2006


Understanding Protein Electrophoresis

ELISA BIO 110 Lab 1. Immunity and Disease

Stem Cell Transplantation

Leukemias and Lymphomas: A primer

Flow Cytometry for Everyone Else Susan McQuiston, J.D., MLS(ASCP), C.Cy.

CONTENT. Chapter 1 Review of Literature. List of figures. List of tables

Lauren Berger: Why is it so important for patients to get an accurate diagnosis of their blood cancer subtype?

Lesson 3 Reading Material: Oncogenes and Tumor Suppressor Genes

Types, production of antibodies and Antibody/antigen interaction

How To Expand Hematopoietic Stem Cells

亞 東 紀 念 醫 院 Follicular Lymphoma 臨 床 指 引

Multiple Myeloma. The term multiple myeloma is considered to be synonymous with myeloma, plasma cell myeloma, active and symptomatic myeloma.

Thymus Cancer. This reference summary will help you better understand what thymus cancer is and what treatment options are available.

CD22 Antigen Is Broadly Expressed on Lung Cancer Cells and Is a Target for Antibody-Based Therapy

Chapter 5: Organization and Expression of Immunoglobulin Genes

A Clinical Primer. for Managed Care Stakeholders

Adult Medical-Surgical Nursing H A E M A T O L O G Y M O D U L E : L E U K A E M I A 2

Understanding the Immune System in Myeloma

Lymphomas after organ transplantation

Shaji Kumar, M.D. Multiple Myeloma: Multiple myeloma (MM) is the second most common hematological

Selective IgA deficiency (slgad)

Immunotherapy for Multiple Myeloma. Sarah Holstein, MD, PhD April 2, 2015 MIR-508

Understanding Protein Electrophoresis

Estimated New Cases of Leukemia, Lymphoma, Myeloma 2014

Understanding series. new. directions LungCancerAlliance.org. A guide for the patient

MALIGNANT LYMPHOMAS. Dr. Olga Vujovic (Updated August 2010)

MEDICAL BREAKTHROUGHS RESEARCH SUMMARY

The Most Common Autoimmune Disease: Rheumatoid Arthritis. Bonita S. Libman, M.D.

co-sponsored by the Health & Physical Education Department, the Health Services Office, and the Student Development Center

Outline of lecture. Disclosures. Current Issues in Practical Hematopathology: Diagnosis of Bone Marrow Lymphomas

From cells to therapeuticsvivalis. Humalex Fully human antibody discovery platform An integrated therapeutic development offering

Recognition of T cell epitopes (Abbas Chapter 6)

Basics of Immunology

One of the more complex systems we re looking at. An immune response (a response to a pathogen) can be of two types:

Multiple Myeloma Workshop- Tandem 2014

Chronic Lymphocytic Leukemia. Case Study. AAIM Triennial October 2012 Susan Sokoloski, M.D.

Lymphoma Diagnosis and Classification

Autoimmunity and immunemediated. FOCiS. Lecture outline

2011 Update on the ECIL-3 guidelines for EBV management in patients with leukemia and other hematological disorders

Transcription:

Pulling the Plug on Cancer Cell Communication Stephen M. Ansell, MD, PhD Mayo Clinic

Why do Waldenstrom s cells need to communicate? Waldenstrom s cells need activating signals to stay alive. WM cells send messages to surrounding cells to prevent themselves from being killed by the immune system Without this communication the cells die

Waldenstrom cells don t grow in isolation - Cell Line Development Unsorted IgM ELISA EBV Screen FACS Functional Studies CD19 + /CD138 + Sorted IgH Gene Analysis Array CGH Gene Expression Analysis

Waldenstrom cells don t grow in isolation Out of 48 specimens 1 cell line (MWCL-1) Diagnosis: Waldenstrom macroglobulinemia, 73 year old male Light Chain: Kappa, BM Involvement: 50%, IgM: 2.4 g/dl, B2M 6.15mcg/ml Unsorted IgM ELISA: Secretes high levels of IgM EBV Screen: EBV positive by PCR FACS: Positive for kappa, CD19, CD20, CD38, CD138, BCMA, TACI Functional Studies: IL-4, IL-6, IL-21, IGF and BAFF IgH gene usage in the tumor biopsy and the cell line is clonal for VH3-15 MYD88 L265P mutation - heterozygous WM cells are fragile and die easily when the communication is removed Hodge et al. Blood. 2011

Why do Waldenstrom s cells need to communicate? Waldenstrom s cells need activating signals to stay alive and function normally Growth BLyS, IL-6 IgM production BLyS, IL-6, IL-21 WM cells send messages to surrounding cells to prevent themselves from being killed by the immune system Shut down the immune response PD-L1 Without this communication the WM cells die

Waldenstrom s cells need activating signals to stay alive and function

Cells communicate by cytokine networks

What s the goal of the communication? Lymphocytes to Plasma cells making Antibodies

What are they talking about? Lymphocytes to plasma cells to antibodies the B-cell receptor pathway

What s are they talking about? Lymphocytes to plasma cells making antibodies the Toll-like receptor pathway

What s the end result? Various types of Immunoglobulins

What went wrong in Waldenström macroglobulinemia? Lymphoplasmacytic infiltrate IgM protein Anemia, lymphadenopathy, hyperviscosity Cell growth and IgM production still depends on communication

Problem 1: The monoclonal protein The protein in WM is IgM, not IgG The protein molecules are all identical The protein production appears poorly controlled High IgM levels can result in clinical symptoms

Problem 2: The malignant lymphoplasmacytic cell Lymphoplasmacytic lymphoma involving either the bone marrow or extramedullary sites Cytologic spectrum - small lymphocytes to well-formed plasma cells High levels of surface CD19, CD20, and immunoglobulin light chain expression

What causes the increased production of IgM in Waldenström macroglobulinemia?

Cytokines are elevated in WM Responsible for cell communication Cytokines are proteins to allow cells to communicate They are secreted after stimulation They play a role in many cell responses They often affect the actions of other cytokines

Cytokines are elevated in WM

B-lymphocyte stimulator (BLyS) Critical for maintaining normal B-cells and for immunoglobulin production Too little BLyS results in absence of B- lymphocytes and low immunoglobulin levels Too much BLyS in mice causes lymphoma

BLyS expression in WM

BLyS increases IgM in WM cells

Where does BLyS come from? Autocrine Paracrine BAFF-R BCMA TACI BLyS APRIL APRIL NF-kB Bcl-2 Bcl-xL Bax Bim BLyS Tumor Environment Malignant B cell

BLyS collaborates with other cytokines including IL-6 and IL-21 to produce IgM

IL-6 expression increased in WM Inflammatory cytokine Causes B-lymphocyte proliferation and differentiation Stimulates T-cell proliferation Serum levels are elevated in WM patients

IL-6 increases IgM levels in WM Increasing amounts of IL-6 increases IgM production IL-6 is controlled by a different cytokine - CCL5

IL-21 expression increased in WM IL-21 produced by T-cells and NK cells Promotes plasma cell growth Prevents death of cancer cells

IL-21 controls plasmacytic differentiation and IL-6 production

CCL5 (Rantes) controls IL-6 in WM CCL5 levels are very high in patients with high IgM levels CCL5 is produced by WM cells Signals through a intracellular protein GLI2

MYD88 Mutations amplify the communication

The role of cytokines in controlling IgM levels in WM

WM cells send messages to surrounding cells to prevent themselves from being killed by the immune system

Waldenstrom cells send messages to immune cells to protect themselves

The role of cytokines in controlling escape from the immune system 0h 24h 72h IL-21 increases the expression of PD-1

PD-1 expressing T cells do not function properly

PD-L1 and PD-L2 that activate PD-1 are highly expressed in WM Normal Marrow WM Marrow PD-L1 PD-L2

Ways to Pull the Plug on Waldenstrom Cell Communication Suppressing cytokine production in general Lenalidomide, JAK/STAT inhibitors, ibrutinib Blocking specific cytokines antibodies to BLyS, IL-6 Blocking suppression of the immune system antibodies to PD-1 and PD-L1

Summary Waldenström macroglobulinemia is a disease with two problems the cancerous cell in the bone marrow or lymph nodes and the protein in the blood. Cytokines made by cells in the tumor microenvironment support the growth of the cancer cell, the production of IgM, and help the cells hide from the immune system. Interfering with cell communication is a new treatment option.

Acknowledgements Anne Novak Denny Grote Steve Ziesmer Grant funding: